Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class

Journal of Clinical Hypertension

Volumn 11, Issue 12, 2009, Pages 743-745

  Bloch, Michael J ^a,b   Basile, Jan N ^c,d  

^a University of Nevada School of Medicine   (United States)

^b Saint Mary's   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; NOTE; PRIORITY JOURNAL; RISK FACTOR; STROKE; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS;

EID: 70849092422     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00207.x     Document Type: Note

References (0)